Authors: Mudatsir M, Yufika A, Nainu F, Frediansyah A, Megawati D doi: https://doi.org/10.3390/scipharm88030036 Abstract The coronavirus disease 2019 (COVID-19) pandemic is a major global threat. With no effective antiviral drugs, the repurposing of many currently available drugs has been considered. One such drug is ivermectin, an FDA-approved antiparasitic agent that has been shown to exhibit [...]

Authors: Chowdhury AT, Shahabz M, Karim MR, Islam J, Guo D, He D. DOI: https://doi.org/10.21203/rs.3.rs-38896/v1 Abstract Background The worldwide COVID-19 pandemic was caused by a newly discovered Coronavirus. The treatment methods for COVID-19 are emerging and rapidly evolving. Existing drugs, including Ivermectin and Hydroxychloroquine, offer the hope of effective treatment in early disease. In this [...]

Authors: Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. DOI:10.3329/jbcps.v38i0.47512 Abstract Background: A definitive treatment of SARS CoV-2 is yet toarrive and the human death toll rises exponentially globally.In this health emergency, it might be useful to look into theold therapies which could be effective against the virus. Invitro research showed [...]

Authors: Maurya DK DOI: 10.26434/chemrxiv.12630539.v1 D O I: 10.26434/chemrxiv.12630539.v1 [opens in a new tab] Abstract The current outbreak of the corona virus disease 2019 (COVID-19), has affected almost entire world and become pandemic now. Currently, there is neither any FDA approved drugs nor any vaccines available to control it. Very recently in Bangladesh, a group [...]

Authors: Gorial FI, Mashhadani S, Sayaly HM, Dakhil BD, AlMashhadani MM. doi: https://doi.org/10.1101/2020.07.07.20145979 Abstract Background To date no effective therapy has been demonstrated for COVID-19. In vitro, studies indicated that ivermectin (IVM) has antiviral effect. Objectives To assess the effectiveness of ivermectin (IVM) as add-on therapy to hydroxychloroquine (HCQ) and azithromycin (AZT) in treatment of [...]

Authors: Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. doi: https://doi.org/10.1101/2020.06.06.20124461 Abstract Importance No therapy to date has been shown to improve survival for patients infected with SARS-CoV-2. Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in vitro but clinical response has not been previously evaluated. Objective To determine [...]

Ivermectin was shown to inhibit severe acute respiratory syndrome coronavirus 2 replication in vitro, which has led to off-label use, but clinical efficacy has not been described previously.

This Pilot clinical trial conducted on hospitalized adult patients with mild to moderate COVID-19 diagnosed according to WHO interim guidance. Sixteen Patients received a single dose of IVM 200Mcg /kg on admission day as add on therapy to hydroxychloroquine (HCQ)and Azithromycin (AZT) and were compared with 71 controls received HCQ and AZT matched in age, gender, clinical features, and comorbidities.

Authors: Chowdhury AT, Shahbaz M, Karim MR, Islam J, Dan G DOI: 10.14744/ejmo.2021.16263 Abstract Objectives: We investigated the outcomes of Ivermectin-Doxycycline vs. Hydroxychloroquine-Azithromycin combination therapy in mild to moderate COVID19 patients. Methods: Patients were divided randomly into two groups: Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for ten days in group A, and Hydroxychloroquine [...]

Authors: Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R PMID: 32473642 PMCID: PMC7261036 DOI: 10.1186/s12941-020-00368-w Abstract The recent report by Caly et al., describing the antiviral potential of ivermectin against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro arrive to the agenda of potential candidates for COVID-19 treatment. This discovery gave [...]